KRX Bio Technology Transfer Index

Yuhan Corp is due to file its H1 2026 interim report by August 14, 2026, creating the next formal earnings and Lazcluze-royalty disclosure catalyst.

Daewoong Pharmaceutical's statutory deadline to submit its H1 2026 semiannual report is 14 August 2026.

Peptron is due to file its 2026 first-half report by August 14, 2026, providing the next scheduled company financial and operating update before September 7.

AprilBio is due to file its 2026 half-year report, containing second-quarter financial results, by August 14.

Hanmi Pharm is scheduled to report 2Q26 results on 2026-07-28, with analysts estimating sharply higher revenue and operating profit chiefly from Lilly's USD 75 million sonefpeglutide upfront payment.

Oscotec disclosed that Kim Seong-yeon and a specially related party became its largest shareholder after completion of founder Kim Jeong-geun's inheritance process, holding 12.45% (38,258,176 shares).

AprilBio completed KRW 346.8 billion of third-party placements, funding R&D and effecting the agreed transfer of management control to TKG Huchems.

LigaChem corrected the disclosed identity of one fund subscriber in its KRW500 billion CPS/CB financing, with the final documents retaining a KRW121,400 conversion price and July 24 payment date.

Kolon TissueGene said the TG-C U.S. commercialization timeline will be delayed and that it will determine its regulatory path after the second Phase 3 readout expected in October 2026.

LigaChem announced that ESMO Congress 2026 accepted two LCB02A abstracts covering preclinical efficacy/safety and the global Phase 1/2 trial design.

GL Pharma obtained MFDS approval for Telmieltan, a four-strength generic of Chong Kun Dang’s Telminuvo hypertension treatment.

Hana Securities forecast SK Biopharmaceuticals’ Q2 2026 revenue of KRW 238.5 billion and operating profit of KRW 88.5 billion, respectively 2.0% and 4.7% above consensus.

AprilBio signed a technology license-in agreement with Curigin for a dual-target siRNA-based metabolic-disease drug candidate.